{"Clinical Trial ID": "NCT00846027", "Intervention": ["INTERVENTION 1:", "Bevacizumab + Paclitaxel + Gemcitabine", "Participants received bevacizumab 10 mg/kg intravenous (IV), paclitaxel 150 mg/m^2 IV and gemcitabine 2000 mg/m^2 IV on day 1 and day 15 of each 4-week cycle until disease progression, unacceptable toxicity or withdrawal of consent."], "Eligibility": ["Incorporation criteria:", "* Female patients aged 18 years.", "- Breast cancer, with measurable, locally recurrent or metastatic lesions, or patients with bone metastases only.", "HER-2 negative disease.", "- Chemotherapy candidates.", "Statement of Operations of the Eastern Cooperative Oncology Group (ECOG) 2.", "- Exclusion criteria:", "Previous chemotherapy for metastatic or locally advanced breast cancer.", "Previous radiotherapy for the treatment of metastatic breast cancer.", "Any prior adjuvant treatment with anthracyclines is completed < 6 months prior to registration.", "Chronic daily treatment with corticosteroids ( 10 mg/day), aspirin (> 325 mg/day) or clopidogrel (> 75 mg/day)."], "Results": ["Performance measures:", "- Survivors without progression", "\u2022 Progression-free survival was defined as the time elapsed between the entry in the study and the first documented progression of the disease using the solid tumour response assessment criteria (RECIST) or the death of any cause, depending on the first of the two contingencies.", "Time frame: Baseline to end of study (up to 2 years and 10 months)", "Results 1:", "Title of the arm/group: Bevacizumab + Paclitaxel + Gemcitabine", "The participants were given bevacizumab 10 mg/kg intravenous (IV), paclitaxel 150 mg/m^2 IV and gemcitabine 2000 mg/m^2 IV on day 1 and day 15 of each 4-week cycle until disease progression, unacceptable toxicity or withdrawal of consent.", "Total number of participants analysed: 90", "Median (95% confidence interval)", "Unit of measure: Month 11.51 (9.01 to 17.59)"], "Adverse Events": ["Undesirable Events 1:", "Total: 21/82 (25.61 per cent)", "Decrease in the number of neutrophils 1/82 (1.22%)", "1/82 (1.22%)", "Left ventricular systolic dysfunction 1/82 (1.22%)", "Hypertension 1/82 (1.22%)", "1/82 (1.22%)", "Anorexia 1/82 (1.22%)", "gastrointestinal perforation value 1/82 (1.22%)", "1/82 (1.22%)", "Dehydration 1/82 (1.22%)", "Diarrhoea 1/82 (1.22%)"]}